ETPrime

Divis Labs - Divi's Laboratories Share Price

  • 6,612.00-19.50 (-0.30%)
  • Volume: 7,86,589
  • Closed
  • Last Updated On: 30 May, 2025, 03:35 PM IST
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Loading...
Divis Labs - Divi's Laboratories Share Price
  • 6,612.00-19.50 (-0.30%)
  • Volume: 7,86,589
Advertisment
Stock Recommendations

  • Potential
    Upside

  • 1 Year
    Target

HOLD

Mean Recos by
24 Analysts

3

7

6

5

3

Strong Sell

Sell

Hold

Buy

Strong Buy

Unlock Potential Upside
Stock Reports Plus

/10

Stock Score

View Report
Earnings
Fundamentals
Relative Valuation
Risk
Price Momentum
No Rating (NR)
Negative
Neutral
Positive
Unlock Stock Score

Divis Labs share price insights

View All

  • In the last 20 years, only 1.39 % trading sessions saw intraday declines higher than 5 % .

  • Company has outstanding debt obligations for the first time in last 5 years. (Source: Consolidated Financials)

  • Company's annual revenue growth of 18.67% outperformed its 3 year CAGR of 2.27%. (Source: Consolidated Financials)

  • 5 day moving crossover appeared yesterday. Average price decline of -2.32% within 7 days of this signal in last 5 years.

  • Divi's Laboratories Ltd. share price moved down by -0.30% from its previous close of Rs 6,631.50. Divi's Laboratories Ltd. stock last traded price is 6,612.00

    Share PriceValue
    Today/Current/Last6,612.00
    Previous Day6,631.506,633.50

InsightsDivis Labs

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Key Metrics

    PE Ratio
    (x)    		80.11
    EPS - TTM
    (₹)    		82.53
    MCap
    (₹ Cr.)    		1,75,527
    Sectoral MCap Rank
    		2
    PB Ratio
    (x)    		11.76
    Div Yield
    (%)    		0.45
    Face Value
    (₹)    		2.00
    Beta

    Beta

    1 Month1.54
    3 Months0.83
    6 Months0.77
    1 Year1.01
    3 Years1.06

    		1.54
    VWAP
    (₹)    		6,600.94
    52W H/L
    (₹)
    6,764.00 / 4,180.50

    Divis Labs Share Price Returns

    1 Day-0.3%
    1 Week1.99%
    1 Month8.62%
    3 Months20.65%
    1 Year49.84%
    3 Years85.39%
    5 Years176.64%

    ET Stock ScreenersTop Score Companies

    Check whether Divis Labs belongs to analysts' top-rated companies list?

    View Stock Screeners

    Divis Labs News & Analysis

    View all Divis Labs Share News & Announcements

    Divis Labs Share Recommendations

    Recent Recos

    HOLD

    Current

    Mean Recos by 24 Analysts

    Strong
    Sell    SellHoldBuyStrong
    Buy
    • Target₹4500
    • OrganizationICICI Securities
    • SELL
    • Target₹3742
    • OrganizationICICI Direct
    • BUY

    Analyst Trends

    RatingsCurrent1 Week Ago1 Month Ago3 Months Ago
    Strong Buy3333
    Buy5545
    Hold6656
    Sell7755
    Strong Sell3355
    # Analysts24242224
    View all Stock Recommendations

    Divis Labs Financials

    • Insights

      • Beating 3 Yr Revenue CAGR

        Company's annual revenue growth of 18.67% outperformed its 3 year CAGR of 2.27%. (Source: Consolidated Financials)

      • Employee & Interest Expense

        Company has spent less than 1% of its operating revenues towards interest expenses and 13.28% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)
      Quarterly | AnnualMar 2025Dec 2024Sep 2024Jun 2024Mar 2024
      Total Income2,671.002,401.002,444.002,197.002,382.00
      Total Income Growth (%)11.25-1.7611.24-7.7722.15
      Total Expenses1,806.001,675.001,721.001,593.001,667.00
      Total Expenses Growth (%)7.82-2.678.04-4.4414.10
      EBIT865.00726.00723.00604.00715.00
      EBIT Growth (%)19.150.4119.70-15.5246.22
      Profit after Tax (PAT)662.00589.00510.00430.00538.00
      PAT Growth (%)12.3915.4918.60-20.0750.28
      EBIT Margin (%)32.3830.2429.5827.4930.02
      Net Profit Margin (%)24.7824.5320.8719.5722.59
      Basic EPS (₹)24.9322.2019.2016.2020.25
      Quarterly | AnnualMar 2025Dec 2024Sep 2024Jun 2024Mar 2024
      Total Income2,623.002,379.002,407.002,142.002,338.00
      Total Income Growth (%)10.26-1.1612.37-8.3822.92
      Total Expenses1,762.001,649.001,671.001,539.001,636.00
      Total Expenses Growth (%)6.85-1.328.58-5.9315.86
      EBIT861.00730.00736.00603.00702.00
      EBIT Growth (%)17.95-0.8222.06-14.1043.27
      Profit after Tax (PAT)667.00594.00518.00430.00531.00
      PAT Growth (%)12.2914.6720.47-19.0248.32
      EBIT Margin (%)32.8330.6930.5828.1530.03
      Net Profit Margin (%)25.4324.9721.5220.0722.71
      Basic EPS (₹)25.1222.3919.5116.1819.99
      Quarterly | Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Revenue9,712.008,184.008,112.179,073.707,031.96
      Total Revenue Growth (%)18.670.89-10.6029.0425.93
      Total Expenses6,796.006,021.005,743.545,390.204,365.92
      Total Expenses Growth (%)12.874.836.5623.4615.97
      Profit after Tax (PAT)2,191.001,600.001,823.382,960.451,984.29
      PAT Growth (%)36.94-12.25-38.4149.1944.15
      Operating Profit Margin (%)31.1727.6030.5041.1238.26
      Net Profit Margin (%)23.4020.3923.4733.0428.47
      Basic EPS (₹)82.5360.2768.69111.5274.75
      Quarterly | Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Revenue9,550.008,002.007,974.318,991.086,861.14
      Total Revenue Growth (%)19.350.35-11.3131.0424.74
      Total Expenses6,621.005,870.005,620.215,314.564,233.27
      Total Expenses Growth (%)12.794.445.7525.5414.81
      Profit after Tax (PAT)2,209.001,576.001,808.152,948.541,954.72
      PAT Growth (%)40.16-12.84-38.6850.8442.40
      Operating Profit Margin (%)31.8527.8530.8741.4138.66
      Net Profit Margin (%)24.0120.5623.7133.2028.75
      Basic EPS (₹)83.2059.3768.11111.0773.63

      All figures in Rs Cr, unless mentioned otherwise

      View Details

    • Insights

      • Undertaking New Debt

        Company has outstanding debt obligations for the first time in last 5 years. (Source: Consolidated Financials)
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Assets16,932.0015,470.0014,438.7713,374.7110,774.07
      Total Assets Growth (%)9.457.147.9624.1426.22
      Total Liabilities1,963.001,899.001,671.681,646.531,479.46
      Total Liabilities Growth (%)3.3713.601.5311.2920.70
      Total Equity14,969.0013,571.0012,767.0911,728.189,294.61
      Total Equity Growth (%)10.306.308.8626.1827.15
      Current Ratio (x)6.947.578.466.995.55
      Total Debt to Equity (x)0.000.000.000.000.00
      Contingent Liabilities0.001,432.00736.981,259.901,107.13
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Assets16,824.0015,362.0014,351.6213,307.8610,723.77
      Total Assets Growth (%)9.527.047.8424.1025.95
      Total Liabilities1,929.001,878.001,646.201,616.511,452.20
      Total Liabilities Growth (%)2.7214.081.8411.3121.28
      Total Equity14,895.0013,484.0012,705.4211,691.359,271.57
      Total Equity Growth (%)10.466.138.6726.1026.72
      Current Ratio (x)7.037.608.567.105.63
      Total Debt to Equity (x)0.000.000.000.000.00
      Contingent Liabilities0.001,432.00736.981,259.901,107.13

      All figures in Rs Cr, unless mentioned otherwise

      View Details

    • Insights

      • Cash from Operations vs PAT

        Operating cash flow of Rs 1653.0 cr is 0.75 times compared to the reported net profit of Rs 2191.0 cr. (Source: Consolidated Financials)

      • Increase in Cash from Investing

        Company has used Rs 804.0 cr for investing activities which is an YoY increase of 198.88%. (Source: Consolidated Financials)
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Net Cash flow from Operating Activities1,653.001,261.002,459.731,911.801,946.93
      Net Cash used in Investing Activities-804.00-269.00-2,707.62-2,194.9275.13
      Net Cash flow from Financing Activities-799.00-799.00-797.17-532.44-34.89
      Net Cash Flow50.00193.00-1,045.06-815.561,987.17
      Closing Cash & Cash Equivalent413.00363.00169.701,214.762,030.32
      Closing Cash & Cash Equivalent Growth (%)13.77113.91-86.03-40.174,605.26
      Total Debt/ CFO (x)0.000.000.000.000.00
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Net Cash flow from Operating Activities1,650.001,266.002,447.951,910.161,947.05
      Net Cash used in Investing Activities-803.00-268.00-2,706.75-2,195.4075.34
      Net Cash flow from Financing Activities-797.00-798.00-796.59-531.50-33.97
      Net Cash Flow50.00200.00-1,055.39-816.741,988.42
      Closing Cash & Cash Equivalent394.00344.00144.171,199.562,016.30
      Closing Cash & Cash Equivalent Growth (%)14.53138.61-87.98-40.517,132.07
      Total Debt/ CFO (x)0.000.000.000.000.00

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Return on Equity (%)14.6311.7814.2825.2421.34
      Return on Capital Employed (%)18.8515.2617.7630.2527.60
      Return on Assets (%)12.9310.3412.6222.1318.41
      Interest Coverage Ratio (x)1,660.00848.004,048.484,994.763,065.41
      Asset Turnover Ratio (x)0.580.520.560.7464.68
      Price to Earnings (x)69.9357.1441.1539.5348.78
      Price to Book (x)10.226.715.889.9710.37
      EV/EBITDA (x)44.9634.2426.1028.5532.23
      EBITDA Margin (%)35.4732.4234.9244.5941.93
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Return on Equity (%)14.8311.6814.2325.2121.08
      Return on Capital Employed (%)19.0215.1317.7330.2927.28
      Return on Assets (%)13.1310.2512.5922.1518.22
      Interest Coverage Ratio (x)3,331.00837.005,185.946,134.953,809.51
      Asset Turnover Ratio (x)0.570.520.550.7463.39
      Price to Earnings (x)69.4457.8041.4939.6849.50
      Price to Book (x)10.276.755.9010.0010.39
      EV/EBITDA (x)44.8234.6926.2628.6132.68
      EBITDA Margin (%)36.2132.7535.3644.9042.40

    Financial InsightsDivis Labs

    • Income (P&L)
    • Balance Sheet
    • Cash Flow

      • Beating 3 Yr Revenue CAGR

        Company's annual revenue growth of 18.67% outperformed its 3 year CAGR of 2.27%. (Source: Consolidated Financials)

      • Employee & Interest Expense

        Company has spent less than 1% of its operating revenues towards interest expenses and 13.28% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)

      • Undertaking New Debt

        Company has outstanding debt obligations for the first time in last 5 years. (Source: Consolidated Financials)

      • Cash from Operations vs PAT

        Operating cash flow of Rs 1653.0 cr is 0.75 times compared to the reported net profit of Rs 2191.0 cr. (Source: Consolidated Financials)

      • Increase in Cash from Investing

        Company has used Rs 804.0 cr for investing activities which is an YoY increase of 198.88%. (Source: Consolidated Financials)

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Divis Labs Share Price Forecast

    • Get multiple analysts’ prediction on Divis Labs

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Divis Labs

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Divis Labs

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    Divis Labs Technicals

    • Bullish / Bearish signals for Divis Labs basis selected technical indicators and moving average crossovers.

      5 Day EMA Crossover

      Bearish signal on daily chart

      Appeared on:

    Divis Labs Peer Comparison

      • CHART
      • TABLE

      • Choose from Peers

          Choose from Stocks

          • 1D
          • 1W
          • 1M
          • 3M
          • 6M
          • 1Y
          • 5Y
          Loading...

        • Ratio Performance

          NAMEP/E (x)P/B (x)ROE %ROCE %ROA %Rev CAGR [3Yr]OPMNPMBasic EPSCurrent RatioTotal Debt/ Equity (x)Total Debt/ CFO (x)
          Divis Labs80.1111.7314.6318.8512.932.2731.1723.4082.536.940.000.00
          Cipla22.453.7816.9021.5714.108.7324.9819.2065.294.250.000.02
          Torrent Pharma56.2314.1525.1728.7012.749.7525.6016.5956.471.190.401.17
          Dr. Reddys18.463.0816.8521.8111.4415.1124.3217.4764.221.920.120.90
          Mankind Pharma51.146.9913.8913.277.1716.7224.0316.3749.281.270.593.53
          Add More
          Annual Ratios (%)

          Choose from Peers

          • Cadila Healthcare
          • Lupin
          • Aurobindo Pharma
          • Alkem Labs
          • Glenmark Pharma

          Choose from Stocks

            See All Parameters

          Peers InsightsDivis Labs

            Do you find these insights useful?

            • hate it

            • meh

            • love it

            Divis Labs Shareholding Pattern

            • Loading...
              Showing Divis Labs Shareholding as on Mar 2025
              CategoryMar 2025Dec 2024Sep 2024Jun 2024
              Promoters51.8951.8951.8951.90
              Pledge0.000.000.000.00
              FII18.0117.9817.2516.16
              DII20.5620.3720.9821.66
              Mutual Funds12.8311.8911.9213.10
              Others9.539.759.8710.28
            • Showing Shareholding as on Mar 2025
              CategoryNo. of SharesPercentage% Change QoQ
              Promoters13,77,55,09051.89 %0.00
              Pledge00.00 %0.00
              FII4,78,12,21118.01 %0.03
              DII5,45,62,07920.56 %0.19
              MF3,40,48,63112.83 %0.93
              Others2,53,39,2009.53 %-0.21

            Divis Labs MF Ownership

            MF Ownership as on 30 April 2025

            View all Mutual Fund Schemes
            Top Searches:
            Divis Labs News Divis Labs Quarterly Results Divis Labs Dividend Divis Labs Q1 ResultsDivis Labs Q2 ResultsDivis Labs Q3 ResultsDivis Labs Q4 Results

            Divis Labs F&O Quote

              • Expiry

              Price

              6,649.50-34.00 (-0.51%)

              Open Interest

              28,31,5008,500 (0.30%)

              OpenHighLowPrev CloseContracts TradedTurnover (₹ Lakhs)
              6,656.006,679.506,588.006,683.504,41629,307.13

              Open Interest as of 30 May 2025

              • Type
              • Expiry
              • Strike Price

              Price

              197.15-16.95 (-7.92%)

              Open Interest

              10,9004,000 (57.97%)

              OpenHighLowPrev CloseContracts TradedTurnover (₹ Lakhs)
              209.15213.85165.85214.103182,175.06

              Open Interest as of 30 May 2025

            Divis Labs Corporate Actions

            • Meeting DateAnnounced onPurposeDetails
              Aug 11, 2025May 19, 2025AGM-
              May 17, 2025May 08, 2025Board MeetingAudited Results & Dividend
              Mar 08, 2025Feb 04, 2025POM-
              Feb 03, 2025Jan 23, 2025Board MeetingQuarterly Results
              Nov 09, 2024Oct 29, 2024Board MeetingQuarterly Results
            • TypeDividendDividend per ShareEx-Dividend DateAnnounced on
              Final1500%30.0Aug 02, 2024May 27, 2024
              Final1500%30.0Aug 11, 2023May 22, 2023
              Final1500%30.0Aug 11, 2022May 23, 2022
              Final1000%20.0Aug 17, 2021May 31, 2021
              Final1500%30.0-May 19, 2025
            • All TypesEx-DateRecord DateAnnounced onDetails
              BonusSep 23, 2015Sep 26, 2015Aug 08, 2015Bonus Ratio: 1 share(s) for every 1 shares held
              BonusJul 30, 2009Aug 01, 2009Jun 06, 2009Bonus Ratio: 1 share(s) for every 1 shares held
              SplitsAug 03, 2007-May 23, 2007Split: Old FV10.0| New FV:2.0

            About Divis Labs

            Divi's Laboratories Ltd., incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 1,75,527.83 Crore) operating in Pharmaceuticals sector. Divi's Laboratories Ltd. key Products/Revenue Segments include Pharmaceuticals, Scrap, Export Incentives and Sale of services for the year ending 31-Mar-2024. Show More

            • Executives

            • Auditors

            • RB

              Ramesh B V Nimmagadda

              Non Exe.Chairman&Ind.Director
              MK

              Murali K Divi

              Managing Director
              KS

              Kiran S Divi

              WholeTime Director & CEO
              NP

              Nilima Prasad Divi

              Whole Time Director
              SD

              S Devendra Rao

              Whole Time Director
              NV

              N V Ramana

              Executive Director
              Show More
            • Price Waterhouse Chartered Accountants LLP

            Industry

            Pharma - Indian

            Key Indices Listed on

            Nifty Next 50, Nifty 100, Nifty 200, + 36 more

            Address

            Divi Towers,1-72/23(P)/DIVIS/303,Cyber Hills, Gachibowli,Hyderabad, Telangana - 500032

            Contact

            [email protected]

            http://www.divislabs.com

            More Details

            Brands

            Divis Labs

            FAQs about Divis Labs share

            • 1. What's Divis Labs share price today and what are Divis Labs share returns ?
              Divis Labs share price is Rs 6,612.00 as on 30 May, 2025, 03:55 PM IST. Divis Labs share price is down by 0.30% based on previous share price of Rs. 6636.0. In last 1 Month, Divis Labs share price moved up by 8.62%.
            • 2. What dividend is Divis Labs giving?
              Divi's Laboratories Ltd. announced an equity dividend of 1500% on a face value of 2.0 amounting to Rs 30 per share on 27 May 2024. The ex dividend date was 02 Aug 2024.
            • 3. What are the returns for Divis Labs share?
              Return Performance of Divis Labs Shares:
              • 1 Week: Divis Labs share price moved up by 1.99%
              • 1 Month: Divis Labs share price moved up by 8.62%
              • 3 Month: Divis Labs share price moved up by 20.65%
              • 6 Month: Divis Labs share price moved up by 7.12%
            • 4. Who is the chairman of Divis Labs?
              Ramesh B V Nimmagadda is the Non Exe.Chairman&Ind.Director of Divis Labs
            • 5. What's the market capitalization of Divis Labs?
              Within the Pharmaceuticals sector, Divis Labs stock has a market cap rank of 2. Divis Labs has a market cap of Rs 1,75,528 Cr.
            • 6. Which are the key peers to Divis Labs?
              Within Pharmaceuticals sector Divis Labs, Cipla Ltd., Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Mankind Pharma Ltd., Zydus Lifesciences Ltd., Lupin Ltd., Aurobindo Pharma Ltd., Alkem Laboratories Ltd., Biocon Ltd. and Glenmark Pharmaceuticals Ltd. are usually compared together by investors for analysis.
            • 7. Who owns Divis Labs?
              Following are the key changes to Divis Labs shareholding:
              • Promoter holding have gone down from 51.9 (30 Jun 2024) to 51.89 (31 Mar 2025)
              • Domestic Institutional Investors holding have gone down from 21.66 (30 Jun 2024) to 20.56 (31 Mar 2025)
              • Foreign Institutional Investors holding has gone up from 16.16 (30 Jun 2024) to 18.01 (31 Mar 2025)
              • Other investor holding have gone down from 10.28 (30 Jun 2024) to 9.53 (31 Mar 2025)
            • 8. What has been highest price of Divis Labs share in last 52 weeks?
              52 Week high of Divis Labs share is Rs 6,764.00 while 52 week low is Rs 4,180.50
            • 9. Who is the Chief Executive Officer of Divis Labs?
              Kiran S Divi is the WholeTime Director & CEO of Divis Labs
            • 10. What are the Divis Labs quarterly results?
              On Consoldiated basis, Divis Labs reported a total income and profit of Rs 2671.00 Cr and Rs 662.00 respectively for quarter ending 2025-03-31. Total Income and profit for the year ending 2025-03-31 was Rs 9712.00 Cr and Rs 2191.00 Cr.
            • 11. What is the CAGR of Divis Labs?
              The CAGR of Divis Labs is 1.1.
            • 12. What is the PE & PB ratio of Divis Labs?
              The PE ratio of Divis Labs stands at 80.35, while the PB ratio is 11.74.
            • 13. How can I quickly analyze Divis Labs stock?
              Divis Labs share can be quickly analyzed on following metrics:
              • Stock's PE is 80.11
              • Price to Book Ratio of 11.76
            • 14. What is the recommendation for Divis Labs - Buy or Sell?
              As per Refinitiv (erstwhile Thomson Reuters), overall mean recommendation by 24 analysts for Divis Labs stock is to Hold. Recommendation breakup is as follows
              • 3 analysts are recommending Strong Buy
              • 5 analysts are recommending to Buy
              • 6 analysts are recommending to Hold
              • 7 analysts are recommending to Sell
              • 3 analysts are recommending Strong Sell

            Trending in Markets

            Top Gainers As on 03:59 PM | 30 May 2025

            MMTC85.77
            22.09 (34.69%)
            ITI Ltd346.60
            67.85 (24.34%)
            Welspun Corp935.55
            173.50 (22.77%)
            IFCI67.42
            12.16 (22.01%)
            GE T&D India 2,241.40
            356.30 (18.90%)

            Top Losers As on 03:59 PM | 30 May 2025

            Welspun India132.66
            -19.40 (-12.76%)
            Gujarat Fluorochem3,553.30
            -472.50 (-11.74%)
            Chambal Fertilisers551.00
            -43.30 (-7.29%)
            Balkrishna Ind.2,472.20
            -188.00 (-7.07%)
            Godawari Power190.48
            -14.31 (-6.99%)

            DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

            DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

            By using this site, you agree to the Terms of Service and Privacy Policy.

            Business News›Markets›Stocks›Stock Price Quotes›Divis Labs Share Price
            The Economic Times
            BrowseCompanies:
            OSZAR »